Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.49 |
| ▸ | MEN1 | O00255 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22801114 | 0.91 | RAB9A (0.51) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL22801041 | 0.90 | SLC2A1 (0.48) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL22801068 | 0.90 | SLC2A1 (0.56) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL22801044 | 0.89 | KMT2A (0.56) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL22801026 | 0.87 | MAPT (0.46) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL22801061 | 0.86 | SLC2A1 (0.48) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL22801109 | 0.86 | KMT2A (0.50) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL22801034 | 0.86 | KDM4E (0.50) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL22801030 | 0.85 | SLC2A1 (0.63) | KMT2AMEN1MAPTRAB9ANPC1 | |
| SCHEMBL22801129 | 0.84 | KMT2A (0.52) | KMT2AMEN1MAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399264-A1 | 4-SUBSTITUTED-2-THIAZOLE AMIDES AS ANTIVIRAL AGENTS | NATIONAL INSTITUTES OF HEALTH | 2020-12-24 | — | — | US | disclosed |
| US-20200399264-A1 | 4-SUBSTITUTED-2-THIAZOLE AMIDES AS ANTIVIRAL AGENTS | NATIONAL INSTITUTES OF HEALTH | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399264-A1 | 4-SUBSTITUTED-2-THIAZOLE AMIDES AS ANTIVIRAL AGENTS | MAVS, ZC3HAV1, EIF2AK2 | KMT2A 2006/4885MEN1 3515/4885MAPT 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.